Results 111 to 120 of about 593,039 (291)

35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort

Dermatology Reports
Background: Adjuvant dabrafenib and trametinib (DT) reduce relapse risk in stage III BRAF-mutant melanoma, but data on recurrence patterns and management after relapse remain scarce.
Italian Melanoma Intergroup
doaj   +1 more source

Guideline on the Management of Melanoma

, 2016
Objective.1. The Guideline for the Management of Melanoma has been developed in an attempt to improve  management through the process of locating the best available evidence on which to base decisions.
Board, Melanoma Advisory
core  

Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis

, 2019
Melanoma is a highly metastatic cancer, and its incidence has increased over the past several decades. Angiogenesis is associated with melanoma metastasis and a poor prognosis.
Massoumi, Ramin,, Yang, Yvying,, Yang, Yvying, Ke, Hengning,, Ke, Hengning, Ramin Massoumi, Zhe, Hong,, Hong Zhe, Massoumi, Ramin, Zhe, Hong, Hengning Ke, Yvying Yang, Lund University.   +12 more
core   +1 more source

Nitride MXenes Beyond Carbides: Bridging the Gap Between Computational Prediction and Experimental Realization

Advanced Functional Materials, EarlyView.
Nitride MXenes remain constrained by a persistent gap between computational prediction and experimental realization. This Review identifies the thermodynamic, kinetic, and chemical barriers limiting their synthesis, critically evaluates emerging fabrication routes, and proposes a multidimensional computational‐experimental framework to accelerate the ...
Naresh Varnakavi, Masoud Soroush
wiley   +1 more source

27 | Real-world data for malignant melanoma stage II adjuvant therapy

Dermatology Reports
Background: Malignant melanoma (MM) is an aggressive cancer with high metastatic potential from early stages. Stage IIB/C MM shows overall survival lower than stage IIIA, with high recurrence risk. Recently, 1-year pembrolizumab or nivolumab was approved
Italian Melanoma Intergroup
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

The genetic evolution of melanoma

, 2018
Melanoma tumors are driven by a hyperactivated mitogen-activated protein kinase (MAPK) signalling pathway, and therefore can generally be classified by mutations within the B-Raf proto-oncogene (BRAF), RAS family of proto-oncogenes, neurofibromin 1 (NF1),
Jönsson, Göran,, Harbst, Katja,, Lund University.   +2 more
core   +2 more sources

26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series

Dermatology Reports
Background: Sonic Hedgehog (SHH) inhibitors, including sonidegib, have emerged as effective therapies for locally advanced basal cell carcinoma (LA-BCC). However, variability in clinical response has been observed.
Italian Melanoma Intergroup
doaj   +1 more source

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma

Cancer Medicine, 2019
Background The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large‐scale Asian studies that include follow‐up data have been reported.
Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murao, Dai Ogata, Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh   +32 more
doaj   +1 more source

Charge‐Reversed Lipid Nanoparticles Enable Encapsulation of Pt2L4 Nanocages for In vivo Anti‐Cancer Treatment

Advanced Materials, EarlyView.
Charge‐reversed lipid nanoparticles (revLNPs) enable efficient encapsulation and delivery of cationic Pt2L4 nanocages. Encapsulation preserves potent anticancer activity while improving circulation, reducing vascular leakage, and promoting favorable biodistribution in vivo.
Renzo A. Knol, Bochuan Hu, Eduard O. Bobylev, Martina Farber, Petrus C. M. Laan, Thomas J. F. Kock, Bauke Fontein, Johanna Erbani, Oscar Escalona‐Rayo, Seline S. Roose, Tom Keijer, Gabriel Forn‐Cuní, B. Ewa Snaar‐Jagalska, Leila Akkari, Joost N. H. Reek, Alexander Kros, Dennis Aschmann   +16 more
wiley   +1 more source